Changeflow GovPing Pharma & Drug Safety Engineered Adeno-Associated Virus Capsid Patent
Routine Notice Added Final

Engineered Adeno-Associated Virus Capsid Patent

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published application EP4139443A2 for an engineered adeno-associated virus (AAV) capsid by Tenaya Therapeutics. The patent application covers AAV capsid proteins modified for enhanced gene therapy delivery, with inventors Christopher A. Reid and Ze Cheng. The application is designated across 36 European states.

What changed

The EPO published patent application EP4139443A2 for an engineered adeno-associated virus capsid developed by Tenaya Therapeutics. The application covers AAV capsid proteins modified through protein engineering for improved gene therapy vector properties. Inventors Christopher A. Reid and Ze Cheng are listed. The patent is classified under C07K 14/005 (peptides, specifically viral proteins) and other related IPC codes including C12N 15/86 (viral vectors) and A61K 48/00 (gene therapy preparations).

For gene therapy developers and biotechnology companies working with AAV-based vectors, this patent grant establishes intellectual property rights that may affect freedom-to-operate considerations. Companies developing AAV gene therapy products should review the patent claims to assess potential licensing requirements or design-around strategies, particularly in the designated European states.

What to do next

  1. Review patent claims for freedom-to-operate analysis
  2. Assess AAV capsid technology competition landscape

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSID

Publication EP4139443A2 Kind: A2 Apr 01, 2026

Applicants

Tenaya Therapeutics, Inc.

Inventors

REID, Christopher A., CHENG, Ze

IPC Classifications

C07K 14/005 20060101AFI20240709BHEP C12N 15/86 20060101ALI20240709BHEP C12N 7/01 20060101ALI20240709BHEP A61K 48/00 20060101ALI20240709BHEP A61P 9/00 20060101ALI20240709BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

C07K 14/005 - Peptides from viruses C12N 15/86 - Viral vectors A61K 48/00 - Gene therapy

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4139443A2
Docket
EP4139443

Who this affects

Applies to
Biotechnology companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent prosecution Gene therapy development Biopharmaceutical R&D
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.